<DOC>
	<DOCNO>NCT01617096</DOCNO>
	<brief_summary>This double-blind , randomise , placebo-controlled study ass safety efficacy silicone elastomer vaginal matrix ring .</brief_summary>
	<brief_title>Phase 3 Safety Effectiveness Trial Dapivirine Vaginal Ring Prevention HIV-1 Women</brief_title>
	<detailed_description>A Multi-Center , Randomized , Double-Blind , Placebo-Controlled Phase 3 Safety Effectiveness Trial Vaginal Matrix Ring Containing Dapivirine Prevention HIV-1 Infection Women . '' MTN-020 enroll approximately 3676 sexually active HIVnegative woman age 18-45 year randomize 1:1 ratio receive either vaginal ring contain 25 mg dapivirine placebo vaginal ring . Rings insert every 28 day 12 consecutive month . MTN expect initiate study August 2012 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Age 18 45 year ( inclusive ) screening , verify per site SOPs ; within range , site may restrict upper age limit per site SOPs , target woman high risk HIV infection Able willing provide write informed consent screen take part study Able willing provide adequate locator information , define site SOPs HIVuninfected base test perform study staff screen enrollment ( per applicable algorithm Appendix II ) Per participant report , sexually active , define vaginal intercourse least 3 month prior screen Using effective method contraception enrollment , intend use effective method duration study participation ; effective method include hormonal method ( except contraceptive ring ) ; intrauterine device ( IUD ) ; sterilization ( participant , define site SOPs ) At screen enrollment , agree participate research study involve drug , medical device , vaginal product , vaccine duration study participation Note : Tampons may use duration trial . Per participant report screening : Intends become pregnant study participation Plans relocate away study site study participation Plans travel away study site 8 consecutive week study participation Is pregnant Note : A documented negative pregnancy test perform study staff require inclusion ; however selfreported pregnancy adequate exclusion study . Currently breastfeed Diagnosed urinary tract infection ( UTI ) Note : Otherwise eligible participant diagnose UTI screen offer treatment may enrol complete treatment symptom resolve . If treatment complete symptom resolve within 28 day obtain informed consent screening , participant may enrol . Diagnosed pelvic inflammatory disease , STI reproductive tract infection ( RTI ) require treatment per current WHO guideline Note : Otherwise eligible participant diagnose screen pelvic inflammatory disease STI/RTI require treatment per WHO guideline — asymptomatic BV asymptomatic candidiasis — offer treatment may enrol complete treatment symptom resolve . If treatment complete symptom resolve within 28 day obtain informed consent screening , participant may enrol . Genital warts require treatment also must treat prior enrollment . Genital wart require therapy define cause undue burden discomfort participant , include bulky size , unacceptable appearance , physical discomfort . Has clinically apparent Grade 2 high pelvic exam finding ( observe study staff ) per Division AIDS Table Grading Severity Adult Pediatric Adverse Events Version 1.0 , December , 2004 ( Clarification date August 2009 ) , Addendum 1Female Genital Grading Table Use Microbicide Studies Note : Cervical bleeding associate speculum insertion and/or specimen collection judge within range normal accord clinical judgment Investigator Record ( IoR ) /designee consider expect nonmenstrual bleeding exclusionary . Note : Otherwise eligible participant exclusionary pelvic exam finding may enrolled/randomized finding improve nonexclusionary severity grade resolve . If improvement nonexclusionary grade resolution document within 28 day provide informed consent screening , participant may enrol . Participant report and/or clinical evidence following : Known adverse reaction study product ( ever ) Known adverse reaction latex ( ever ) Chronic vaginal candidiasis Nontherapeutic injection drug use 12 month prior Screening Postexposure prophylaxis ( PEP ) HIV exposure within 6 month prior enrollment Last pregnancy outcome 90 day less prior enrollment Gynecologic genital procedure ( e.g. , tubal ligation , dilation curettage , pierce ) 90 day less prior enrollment Recent participation research study involve drug , medical device , vaginal product , vaccine , within 60 day enrollment Participation MTN003 , Vaginal Oral Interventions Control Epidemic ( VOICE ) clinical trial , HIV prevention study use systemic topical antiretroviral medication , within 12 month enrollment As determined IoR/designee , significant uncontrolled active chronic cardiovascular , renal , liver , hematologic , neurologic , gastrointestinal , psychiatric , endocrine , respiratory , immunologic disorder infectious disease , include active tuberculosis Has follow laboratory abnormality Screening Visit : Aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) Grade 1 high per Division AIDS Table Grading Severity Adult Pediatric Adverse Events Version 1.0 , December , 2004 ( Clarification date August 2009 ) Creatinine Grade 2 high per Division AIDS Table Grading Severity Adult Pediatric Adverse Events Version 1.0 , December , 2004 ( Clarification date August 2009 ) Hemoglobin Grade 2 high per Division AIDS Table Grading Severity Adult Pediatric Adverse Events Version 1.0 , December , 2004 ( Clarification date August 2009 ) Platelet count Grade 1 high per Division AIDS Table Grading Severity Adult Pediatric Adverse Events Version 1.0 , December , 2004 ( Clarification date August 2009 ) Pap result Grade 2 high accord Female Genital Grading Table Use Microbicide Studies Addendum 1 DAIDS Table Grading Adult Pediatric Adverse Events , Version 1.0 , December 2004 ( Clarification date August 2009 ) Note : Otherwise eligible participant exclusionary test may retested screen process . Note : Women document normal result within 12 month prior enrollment need Pap smear screening period . Women Grade 1 abnormal Pap smear enrol upon completion initial phase evaluation current treatment indicate ( base local standard care management abnormal cervical cytology ) . Need repeat Pap within 6 month preclude enrollment prior result become available . Has condition , opinion IoR/designee , would preclude informed consent , make study participation unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>HIV Infections</keyword>
	<keyword>Anti-HIV agent</keyword>
	<keyword>HIV-1</keyword>
</DOC>